BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

From Staging to Survival: How AI-Driven Histological Analysis Is Solving Colorectal Cancer's Overtreatment Problem

The hidden cost of getting treatment decisions wrong Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide, ranking among the ...

April 02, 2026 | Expert Insight | By Dr. Torbjørn Furuseth, CEO and Co-Founder, DoMore Diagnostics

Takeda Reports Strong Phase 3 Results For Zasocitinib In Plaque Psoriasis

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A signifi...

March 30, 2026 | News

BrightGene Reports Positive Phase 1 Results For Oral GLP 1 GIP Agonist BGM0504

BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing BrightGene Bio-Medical Technology C...

March 26, 2026 | News

Celosia Therapeutics Initiates Phase 1b Trial Of CTx1000 Targeting TDP 43 In ALS

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS Celosia Therapeutics, an Australian biotech company developing advanced gen...

March 25, 2026 | News

Alphamab Oncology Initiates Phase III Study Of Anbenitamab In HER2 Positive Breast Cancer

Alphamab Oncology announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN02...

March 25, 2026 | News

Prestige Biopharma Reports Phase 3 Success For HD204 Demonstrating Clinical Equivalence In Advanced NSCLC

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung can...

March 25, 2026 | News

Dizal Reports ZEGFROVY Achieves Superior Progression Free Survival In Phase 3 WU KONG28 Trial For EGFR Exon20ins NSCLC

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over pla...

March 23, 2026 | News

Taiwan Strengthens Its Position In Asia’s Next Phase Of Bioprocessing Growth

Taiwan’s bioprocessing and biotechnology sector has moved from a predominantly research-and-services footing toward a more industrialised, globally c...

March 20, 2026 | Analysis

Eurofins Biomnis Develops LC MS MS Method For Detecting Cereulide Toxin In Human Stool Samples

Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announ...

March 12, 2026 | News

Ascletis Reports Positive Phase II Results For Monthly ASC30 Injection In Obesity Treatment

- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of ...

March 11, 2026 | News

Top 5 ABA Practice Management Software Compared: Features & Pricing (2026)

The ABA software market has grown considerably, and the range of options can make comparison difficult. Platforms vary widely in how they handle clinical d...

March 04, 2026 | News

Lynk Pharmaceuticals Reports Positive Phase III Results For Zemprocitinib In Atopic Dermatitis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammat...

March 03, 2026 | News

Genentech Reports Phase III Success For Fenebrutinib With 51 Percent Relapse Reduction In Multiple Sclerosis

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relap...

March 03, 2026 | News

Blueprint Medicines Showcases Four Year AYVAKIT Data Reinforcing Durable Benefit In Indolent Systemic Mastocytosis

-- Real-world study of AYVAKIT highlights improvement across ISM symptoms -- -- 12 data presentations at 2026 AAAAI Annual Meeting reflect company's ...

March 02, 2026 | Report

Stay Connected